VERA FY2025 SEC EDGAR DEF 14A #163 of 168 in industry

Vera Therapeutics, Inc. CEO pay ratio

The CEO earned $7.0M in FY2025 against median worker pay of $428,720 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-09
Industry
Chemicals & Pharmaceuticals
Industry rank
#163/168

Data updated August 2026

Subscribe to Vera Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
3:1
Below Average (Scale: 0–1000:1)
CEO pay
$7.0M
Median worker
$428,720

Answer first

Vera Therapeutics, Inc.'s FY2025 CEO total of $7.0M ranks #772 of 1,423 complete filings; its 3:1 pay ratio ranks #1387. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $428,720. Industry placement uses the FY2025 SIC-28 peer cohort (# 163 of 168, 4th percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#772
$7.0M of 1,423 FY2025
Ratio rank
#1387
3:1 of 1,423
Industry pct
4th
among the lower quartile of industry peers by pay ratio

How Vera Therapeutics, Inc. ranks nationally

Vera Therapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$6,986,410 46th percentile higher than 46% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). This entry sits in this band. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Vera Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($7.0M) against pay ratio (3:1) for Vera Therapeutics, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02069254.34138508.56207762.88277017.10:111:122:133:144:1CEO total payPay ratio (CEO : median worker)Vera Therapeutics, Inc., CEO total pay: 6986410 · Pay ratio (CEO : median worker): 3:1Vera Therapeutics, Inc.Summit Therapeutics Inc., CEO total pay: 1025895 · Pay ratio (CEO : median worker): 3:1Summit Therapeutics Inc.Highwater Ethanol LLC, CEO total pay: 394644 · Pay ratio (CEO : median worker): 4:1Highwater Ethanol LLCTwist Bioscience Corp, CEO total pay: 376416 · Pay ratio (CEO : median worker): 2:1Twist Bioscience CorpViridian Therapeutics, Inc.\DE, CEO total pay: 6776249 · Pay ratio (CEO : median worker): 4:1Viridian Therapeutics, Inc.\DERoyalty Pharma plc, CEO total pay: 349893 · Pay ratio (CEO : median worker): 4:1Royalty Pharma plc
Vera Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Vera Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
3:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$7.0M
Companies in Industry
168
vs. Industry Median
Below
#163 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Vera Therapeutics, Inc.: near-parity Item 402(u) ratio

Vera Therapeutics, Inc.'s FY2025 ratio 3:1 ranks #163 of 168 Chemicals & Pharmaceuticals filers (4th percentile). the CEO earned 3× the median employee ($428,720) in FY2025.

At $428,720 median worker pay, the FLOOR stamp is near pay-parity territory under HEAVY CEO total.

CEO Total Pay

$7.0M

FY2025 Summary Compensation, below median

Pay Ratio

3:1

Below typical

Vera Therapeutics, Inc. in the lower Chemicals & Pharmaceuticals third

Vera Therapeutics, Inc.'s FY2025 ratio 3:1 ranks #163 of 168 Chemicals & Pharmaceuticals filers (4th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Vera Therapeutics, Inc.'s $7.0M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #772 and ratio rank #1387 split - treat 3:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$7.0M
Median Employee Pay
$428,720
Pay Ratio
3:1
Filing Date
2026-04-09

Company Info

Ticker
VERA
CIK
1831828
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1831828, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Vera Therapeutics, Inc.'s FY2025 ratio 3:1 ranks #163 of 168 Chemicals & Pharmaceuticals filers (4th percentile).

Read with Vera Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · HEAVY · ELITE-MED.

Seaboard Corp /de/ · HEAVY

ABS(ceo_total_comp) peer at $7.0M (Δ $10K heavier vs Vera Therapeutics, Inc.); STEEP · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Valley National Bancorp · HEAVY

ABS(ceo_total_comp) peer at $7.0M (Δ $12K heavier vs Vera Therapeutics, Inc.); MID · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Atmus Filtration Technologies Inc. · HEAVY

ABS(ceo_total_comp) peer at $7.0M (Δ $17K heavier vs Vera Therapeutics, Inc.); STEEP · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
ONESPAWORLD HOLDINGS Ltd · HEAVY

ABS(ceo_total_comp) peer at $7.0M (Δ $39K heavier vs Vera Therapeutics, Inc.); STEEP · LOW-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Summit Therapeutics Inc. (SIC 28 pole)

Summit Therapeutics Inc. stamps FLOOR · LIGHT nearest in-SIC by ABS(pay_ratio) to Vera Therapeutics, Inc.'s FLOOR filing.
National dual ranks · #772/#1387

Vera Therapeutics, Inc.'s FY2025 package sits #772 by CEO dollars and #1387 by ratio under HEAVY · FLOOR.
Ratio primer · FLOOR

Vera Therapeutics, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Vera Therapeutics, Inc. (CIK 1831828), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.